Track topics on Twitter Track topics that are important to you
Mechelen, Belgium; 12 April 2018, 22.01 CET - Galapagos announces the design of a worldwide Phase 3 program, based on feedback from the FDA and EMA, to evaluate GLPG1690 in patients with idiopathi...
Original Article: Galapagos NV: Galapagos announces ISABELA Phase 3 program in IPFNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...